AIVF Company Profile

Background

AIVF is a Tel Aviv-based healthtech startup founded in 2018 by clinical embryologist Daniella Gilboa and reproductive endocrinologist Prof. Daniel Seidman. The company is dedicated to revolutionizing in-vitro fertilization (IVF) by integrating artificial intelligence (AI) to enhance success rates, accessibility, and affordability of reproductive technologies. AIVF's mission is to transform the fertility journey through cutting-edge technologies and personalized care, aiming to make parenthood achievable for individuals and couples facing fertility challenges.

Key Strategic Focus

AIVF's strategic focus centers on:

AI-Powered IVF Solutions: Developing and deploying AI-driven platforms to optimize embryo evaluation and selection processes.

Clinic Digitization: Offering comprehensive digital tools to streamline IVF clinic operations, enhancing efficiency and patient outcomes.

Global Expansion: Extending the reach of its technologies to fertility clinics worldwide, with a particular emphasis on the U.S. and European markets.

Financials and Funding

AIVF has secured significant funding to support its growth and technological advancements:

Seed Round (May 2018): Raised $6.38 million.

Series A (June 2022): Secured $25 million, led by Insight Partners, with participation from Adam Neumann's Family Office.

These funds are allocated towards accelerating the adoption of AIVF's EMA platform in the U.S. and Europe, expanding the team, and developing new fertility tools.

Pipeline Development

AIVF's primary product, the EMA™ platform, is an AI-powered system designed to evaluate embryo viability during IVF procedures. Key developments include:

CE Mark Approval (2021): EMA received the CE Mark, indicating compliance with European health, safety, and environmental protection standards.

Non-Invasive AI-Based Embryo Evaluation (2024): Launched the first AI-based embryo evaluation for euploidy screening based on time-lapse videos, refining genetic quality assessment of embryos.

Technological Platform and Innovation

AIVF's EMA platform stands out due to its:

Proprietary AI Algorithms: Utilizing deep-learning models trained on extensive datasets of embryos with known clinical outcomes to assess embryo quality and developmental competence.

Integration with Time-Lapse Imaging: Analyzing biological data from embryos from fertilization to Day 5 or 6, scoring them based on their probability of successful implantation and pregnancy.

Non-Invasive Genetic Screening: Offering AI-driven, non-invasive tools for genetic quality assessment, reducing the need for traditional invasive procedures.

Leadership Team

Daniella Gilboa: Co-founder and CEO. Transitioned from a clinical embryologist to CEO, leveraging her expertise to lead AIVF's innovations in IVF technology.

Prof. Daniel Seidman: Co-founder and Chief Medical Officer. A reproductive endocrinologist and IVF expert, contributing extensive clinical knowledge to the company's developments.

Dr. Carol Lynn Curchoe: Director of Medical Affairs. Joined AIVF following the acquisition of ART Compass, bringing expertise in IVF lab management.

Leadership Changes

In October 2022, AIVF acquired ART Compass, a leading application for IVF laboratory management. Following this acquisition, Dr. Carol Lynn Curchoe, founder of ART Compass, joined AIVF as Director of Medical Affairs.

Competitor Profile

Market Insights and Dynamics

The global IVF market is valued at approximately $50 billion, with increasing demand driven by rising infertility rates and advancements in reproductive technologies.

Competitor Analysis

Key competitors include:

Alife Health: Offers AI-powered tools to assist clinicians and embryologists in optimizing IVF treatments and streamlining workflows.

Fairtility: Develops transparent AI solutions for embryo quality assessment, aiming to enhance IVF success rates.

ImVitro: Provides AI-driven platforms for embryo evaluation, focusing on improving imaging processes in IVF clinics.

Strategic Collaborations and Partnerships

Genea Biomedx Partnership (May 2023): Integrated AIVF's EMA platform with Genea Biomedx's Geri® time-lapse incubator, combining imaging capabilities with AI analytics to enhance IVF success rates.

Operational Insights

AIVF's strategic initiatives include:

Acquisition of ART Compass (October 2022): Enhanced lab management capabilities, expanding the company's offerings and strengthening its position in the U.S. market.

Global Expansion: EMA platform is commercially available across Europe, Australia, Brazil, South Korea, and North America, with preparations underway for a U.S. launch.

Strategic Opportunities and Future Directions

AIVF is poised to:

Expand Market Presence: Continue penetrating global markets, particularly in the U.S. and Europe.

Innovate AI Solutions: Develop new AI-driven tools to further enhance IVF success rates and patient experiences.

Foster Industry Partnerships: Collaborate with leading fertility clinics and technology providers to drive innovation and adoption of AI in reproductive healthcare.